Health Canada
www.hc-sc.gc.ca
Common menu bar links
Incident Report
Subform I: General Information
1. Report Type.
New incident report
Incident Report Number: 2015-3971
2. Registrant Information.
Registrant Reference Number: 20150305
Registrant Name (Full Legal Name no abbreviations): Bayer CropScience Inc.
Address: Suite 200, 160 Quarry Park Blvd SE
City: Calgary
Prov / State: AB
Country: Canada
Postal Code: T2C 3G3
3. Select the appropriate subform(s) for the incident.
Scientific Study
4. Date registrant was first informed of the incident.
5. Location of incident.
6. Date incident was first observed.
Product Description
7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.
Active(s)PMRA Registration No. 23590 PMRA Submission No. EPA Registration No.
Product Name: Oxadiazon Technical
- Active Ingredient(s)
- OXADIAZON
7. b) Type of formulation.
Application Information
8. Product was applied?
Unknown
9. Application Rate.
10. Site pesticide was applied to (select all that apply).
11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).
To be determined by Registrant
12. In your opinion, was the product used according to the label instructions?
Unknown
Subform VII: Scientific Study
1. Study Reference
Title RP017272 Acute Toxicity (48 hours) to Daphnids (daphnia magna) under Semi-StaticConditions
Date 22-JAN-97
2. a) Is an extension needed to translate the document?
No
3. Type of incident identified in the study
Increased health or environmental risk
4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)
BCS is submitting new information to PMRA related to oxadiazon technical. This information is not necessarily a new adverse effect of the subject chemical, but is rather new information submitted for agencys own review and evaluation. This study documents an acute toxicity assessment of a minor metabolite of oxadiazon. The EC50 for the metabolite (AE 0618784) is lower than that for the parent oxadiazon however this metabolite was only observed to form under certain conditions and then only up to 2 percent of the parent molecule. Therefore, it is unlikely that this new information will significantly impact the risk assessment for oxadiazon uses.
5. a) Was the study discontinued before completion?
No
